Choose by clinical fit, not a universal winner
A medication comparison should begin with the reason for treatment, clinical history, other medicines and the product’s labeled indication. A trial average cannot predict a personal result or establish that the drug with the largest average loss is appropriate for every patient. Ask a clinician to compare benefits, risks and practical constraints for you.
Prescription weight-management medicine is used alongside nutrition and physical activity, and can be part of a long-term plan. Discuss what continuing, changing or stopping treatment would mean. A low-cost entry offer is not a reason to select a medicine that does not fit your care needs.
Sources: Prescription Medications to Treat Overweight & Obesity - NIDDK
Approved options now include different routes
Wegovy contains semaglutide and has injectable and oral tablet formulations. Zepbound contains tirzepatide and is an injectable product. Foundayo contains orforglipron and is an oral GLP-1 option approved in 2026 for eligible adults. These medicines have distinct dose schedules and administration instructions.
Oral Wegovy requires morning fasting, limited water and a waiting period before food, beverages and other oral medicines. Foundayo can be taken with or without food. Weekly injections have a different routine. Do not infer dose equivalence across ingredients or routes.
Sources: Wegovy prescribing information · Zepbound prescribing information · Foundayo prescribing information
Diabetes brands and obesity brands are not interchangeable claims
Ozempic contains semaglutide and Mounjaro contains tirzepatide, but their labeled uses differ from the weight-management brands. A clinician may discuss prescribing decisions beyond a label in a particular situation; that is different from calling every diabetes product FDA-approved for weight loss.
The exact brand, product, dose and formulation matter for eligibility, insurance, instructions and evidence. Avoid comparisons that mix a branded trial result with the price of a different compounded preparation.
Sources: Ozempic prescribing information · Mounjaro prescribing information · Wegovy prescribing information · Zepbound prescribing information
Safety and tolerability are part of effectiveness
The current labels cover gastrointestinal adverse reactions and precautions involving pancreatitis, gallbladder problems, kidney injury related to dehydration and hypoglycemia with certain other diabetes medicines. They also have thyroid-tumor warnings and contraindications that need discussion. A general comparison cannot complete that review for you.
Tell the clinical team about pregnancy plans, contraception, upcoming surgery or procedures, previous treatment and the full medicine list. Follow the product-specific schedule and ask about symptoms before increasing the dose. Persistent severe abdominal pain, repeated vomiting or signs of dehydration require prompt attention.
Sources: Wegovy prescribing information · Zepbound prescribing information · Foundayo prescribing information
Access and evidence should be compared together
Compare the cost of clinical care and medicine, the maintenance-dose price and any insurance or savings conditions. A prepaid monthly equivalent differs from a recurring monthly charge. Make sure the provider can explain follow-up and prescription continuity as well as the first payment.
Compounded medicines are not FDA-approved, and approved-product trial results do not validate every compounded formulation. FDA’s current advice and the specific medical rationale belong in the conversation. We do not rank medicine quality or clinical providers using fictional patient outcomes.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA · FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA